Scinai Immunotherapeutics Announces Results of 2026 Annual Meeting of Shareholders
On June 16, 2026, Scinai Immunotherapeutics Ltd. held its Annual Meeting of Shareholders, where several key proposals were approved. Shareholders re-elected Mr. Sam Moed and Dr. Yael Margolin to the Board of Directors for three-year terms, and Mr. Adi Raviv for a two-year term. A significant corporate action was approved to amend the Companyβs Articles of Association to increase the number of authorized Ordinary Shares. Regarding executive compensation and governance, shareholders approved an amendment to the employment agreement of CEO Amir Reichman, alongside a grant of restricted share units (RSUs) as his 2026 long-term incentive award. Additionally, an extension of the service agreement for Chairman Mark Germain was approved, including a special RSU grant for his recent efforts. Finally, the appointment of Zvi Haft (BDO) as the company's auditors for 2026 was ratified. A total of 2,544,796,000 ordinary shares (636,199 ADSs) were represented at the meeting, constituting a quorum.